Grifols A : Market watchdog sees relevant and significant deficiencies in the accounts, yet Grifols only gets a slap on the wrist
>Report finds deficiencies yet the company gets away with a light punishment - The Spanish market watchdog (CNMV) has finally issued its long-awaited report on Grifols’ unorthodox accounting methods. After reading it, we extract the following main conclusions: i) CNMV has found ‘relevant and significant deficiencies’ in the accounts, ii) besides pointing out the faults, the watchdog does not inquire further into what led the managers to proceed that way nor has any k...Grifols is engaged in developing, manufacturing and distributing a range of plasma derivative products. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend the lives of individuals who suffer from chronic and acute conditions. Co. also specializes in providing infusion solutions, nutrition products, medical devices, diagnostic instrumentation and reagents for use in hospitals and clinics. Co.'s products and services are used by healthcare providers in approximately 100 countries. Co.'s business is organized into three divisions: Bioscience, Diagnostic, Hospital and Raw Materials.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.